Text Education About Cardiovascular Health and HIV (TEACH-HIV)
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 29, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The TEACH-HIV trial is studying how educational text messages can help people living with HIV reduce their risk of heart problems. The goal is to see if sending these messages can encourage healthier habits and ultimately lead to better heart health for individuals who are HIV positive.
To participate in this study, you need to be at least 40 years old, speak English, and be HIV positive. Unfortunately, if you already have serious heart disease, are pregnant, cannot provide consent, or do not have a smartphone, you won't be able to join. If you do participate, you can expect to receive helpful text messages that provide information and tips on managing your cardiovascular health alongside your HIV treatment. This trial is currently recruiting participants, so it’s a great opportunity to contribute to important research while also getting support for your health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HIV positive
- • At least 40 years of age
- • English-speaking
- Exclusion Criteria:
- • Existing clinical atherosclerotic cardiovascular disease (ASCVD)
- • Pregnant
- • Unwilling/unable to provide informed consent
- • Does not own a smartphone
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Patients applied
Trial Officials
Megan McLaughlin, MD, MPH
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials